Questcor (QCOR -34.5%) is getting hammered this morning on another negative report from Citron...
Questcor (QCOR -34.5%) is getting hammered this morning on another negative report from Citron Research. Citron is saying that Aetna (AET -0.5%) has dropped almost all coverage of QCOR's drug Achtar for treating multiple sclerosis and nephrotic symdrome, saying that studies found no proof of efficacy to substantiate reimbursement. It will, however, continue to provide reimbursement when treating infantile spasms.
From other sites
at Nasdaq.com (Apr 9, 2015)
at Zacks.com (Mar 24, 2015)
at Zacks.com (Mar 6, 2015)
at Nasdaq.com (Mar 3, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs